Wedelolactone ameliorates synovial inflammation and cardiac complications in a murine model of collagen-induced arthritis by inhibiting NF-κB/NLRP3 inflammasome activation

Cao, Jingjing; Ni, Yanhui; Ning, Xiaoran; Zhang, Huaxing

doi:10.5603/fhc.a2022.0025

Cited by 8 publications

(9 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scropolioside B, isolated from a Tibetan medicine, Scrophularia dentada Royle ex Benth., could inhibit NF-κB activity, reduce NLRP3 expression, and suppress the maturation and release of IL-1β, suggesting its therapeutic potential in RA and its associated atherosclerosis [ 139 ]. Cao and colleagues demonstrated that Wedelolactone, derived from Eclipta alba, could ameliorate synovial inflammation, cardiac complications, and fibrosis by inhibiting the activation of the NF-κB/NLRP3 inflammasome pathway [ 140 ].…”

Section: Therapeutic Potential By Targeting the Nlrp3 Inflammasomementioning

confidence: 99%

“…HCQ, one of the csDMARDs, may have maculopapular rash, retinopathy, ototoxicity, myopathy, or cardiotoxicity [ 167 , 168 , 169 , 170 ]. The use of IL-β inhibitors, such as anakinra and canakinumab, may exhibit injection site reactions (ISRs) and increase the risk of infection [ 140 , 141 ]. The most common side effect of IL-18BP is ISRs [ 171 ].…”

Section: Therapeutic Potential By Targeting the Nlrp3 Inflammasomementioning

confidence: 99%

See 1 more Smart Citation

The NLRP3 Inflammasome as a Pathogenic Player Showing Therapeutic Potential in Rheumatoid Arthritis and Its Comorbidities: A Narrative Review

Chen,

Tang,

Chen

2024

IJMS

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease characterized by chronic synovitis and the progressive destruction of cartilage and bone. RA is commonly accompanied by extra-articular comorbidities. The pathogenesis of RA and its comorbidities is complex and not completely elucidated. The assembly of the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome activates caspase-1, which induces the maturation of interleukin (IL)-1β and IL-18 and leads to the cleavage of gasdermin D with promoting pyroptosis. Accumulative evidence indicates the pathogenic role of NLRP3 inflammasome signaling in RA and its comorbidities, including atherosclerotic cardiovascular disease, osteoporosis, and interstitial lung diseases. Although the available therapeutic agents are effective for RA treatment, their high cost and increased infection rate are causes for concern. Recent evidence revealed the components of the NLRP3 inflammasome as potential therapeutic targets in RA and its comorbidities. In this review, we searched the MEDLINE database using the PubMed interface and reviewed English-language literature on the NLRP3 inflammasome in RA and its comorbidities from 2000 to 2023. The current evidence reveals that the NLRP3 inflammasome contributes to the pathogenesis of RA and its comorbidities. Consequently, the components of the NLRP3 inflammasome signaling pathway represent promising therapeutic targets, and ongoing research might lead to the development of new, effective treatments for RA and its comorbidities.

show abstract

Section: Therapeutic Potential By Targeting the Nlrp3 Inflammasomementioning

confidence: 99%

Section: Therapeutic Potential By Targeting the Nlrp3 Inflammasomementioning

confidence: 99%

The NLRP3 Inflammasome as a Pathogenic Player Showing Therapeutic Potential in Rheumatoid Arthritis and Its Comorbidities: A Narrative Review

Chen,

Tang,

Chen

2024

IJMS

View full text Add to dashboard Cite

show abstract

“…As with many other medical conditions, 'autoimmune' disorders seem invariably to be associated with an increase in pro-inflammatory transcription factors, including NF-kB [98] and YY1 [99]. This may be an important commonality as both NF-kB and YY1 can upregulate the mitochondrial melatonergic pathway, which may be crucial in determining the course of activation-deactivation in immune cells [63,64].…”

Section: B-cells Antibodies and Mitochondriamentioning

confidence: 99%

“…Notably, MDD pathophysiology seems highly heterogenous [189], with astrocytes being an important hub in coordinating changes in neuronal activity and interarea patterned neuronal activity in the brain [4,179]. However, MDD samples in any given study show significant heterogeneity in physiological indices, the investigation of which should better define the classification and treatment not only of MDD [98,190], but of the associations of MDD with autoimmune disorders.…”

Section: Autoimmunity and Psychiatric Disordersmentioning

confidence: 99%

Redefining Autoimmune Disorders’ Pathoetiology: Implications for Mood and Psychotic Disorders’ Association with Neurodegenerative and Classical Autoimmune Disorders

Anderson¹,

Almulla

Reíter

et al. 2023

Cells

View full text Add to dashboard Cite

Although previously restricted to a limited number of medical conditions, there is a growing appreciation that ‘autoimmune’ (or immune-mediated) processes are important aspects of a wide array of diverse medical conditions, including cancers, neurodegenerative diseases and psychiatric disorders. All of these classes of medical conditions are associated with alterations in mitochondrial function across an array of diverse cell types. Accumulating data indicate the presence of the mitochondrial melatonergic pathway in possibly all body cells, with important consequences for pathways crucial in driving CD8+ T cell and B-cell ‘autoimmune’-linked processes. Melatonin suppression coupled with the upregulation of oxidative stress suppress PTEN-induced kinase 1 (PINK1)/parkin-driven mitophagy, raising the levels of the major histocompatibility complex (MHC)-1, which underpins the chemoattraction of CD8+ T cells and the activation of antibody-producing B-cells. Many factors and processes closely associated with autoimmunity, including gut microbiome/permeability, circadian rhythms, aging, the aryl hydrocarbon receptor, brain-derived neurotrophic factor (BDNF) and its receptor tyrosine receptor kinase B (TrkB) all interact with the mitochondrial melatonergic pathway. A number of future research directions and novel treatment implications are indicated for this wide collection of poorly conceptualized and treated medical presentations. It is proposed that the etiology of many ‘autoimmune’/‘immune-mediated’ disorders should be conceptualized as significantly determined by mitochondrial dysregulation, with alterations in the mitochondrial melatonergic pathway being an important aspect of these pathoetiologies.

show abstract

“…These include traditional Chinese medicine formulas such as the Jinwujiangu capsule for treating RA [196], Baihu-Guizhi decoction [197], and Qi-Sai-Er-Sang-Dang-Song decoction [198]. Additionally, bioactive compounds extracted from plants, such as the monomer derivative of paeoniflorin [199], wedelolactone derived from Xanthium sibiricum [200], licoriceprocessed DGN products containing Huangruixiang [201], a combination of mangiferin and cinnamic acid [202], punicalagin [203], tectoridin [204], strychnine combined with Atractylodes Macrocephala [205], and pinocembrin from the genus Pinus [206], have also shown activity through this pathway.…”

Section: Regulating the Tlr4/nlrp3/nf-kb/gsdmd Signaling Pathwaymentioning

confidence: 99%

New Potentiality of Bioactive Substances: Regulating the NLRP3 Inflammasome in Autoimmune Diseases

Chen,

Wang,

Chen

2023

Nutrients

View full text Add to dashboard Cite

The NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome is an essential component of the human innate immune system, and is closely associated with adaptive immunity. In most cases, the activation of the NLRP3 inflammasome requires priming and activating, which are influenced by various ion flux signals and regulated by various enzymes. Aberrant functions of intracellular NLRP3 inflammasomes promote the occurrence and development of autoimmune diseases, with the majority of studies currently focused on rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis. In recent years, a number of bioactive substances have shown new potentiality for regulating the NLRP3 inflammasome in autoimmune diseases. This review provides a concise overview of the composition, functions, and regulation of the NLRP3 inflammasome. Additionally, we focus on the newly discovered bioactive substances for regulating the NLRP3 inflammasome in autoimmune diseases in the past three years.

show abstract

Wedelolactone ameliorates synovial inflammation and cardiac complications in a murine model of collagen-induced arthritis by inhibiting NF-κB/NLRP3 inflammasome activation

Abstract: This article has been peer reviewed and published immediately upon acceptance.It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Folia Histochemica et Cytobiologica" are listed in PubMed.

Cited by 8 publications

References 53 publications

The NLRP3 Inflammasome as a Pathogenic Player Showing Therapeutic Potential in Rheumatoid Arthritis and Its Comorbidities: A Narrative Review

The NLRP3 Inflammasome as a Pathogenic Player Showing Therapeutic Potential in Rheumatoid Arthritis and Its Comorbidities: A Narrative Review

Redefining Autoimmune Disorders’ Pathoetiology: Implications for Mood and Psychotic Disorders’ Association with Neurodegenerative and Classical Autoimmune Disorders

New Potentiality of Bioactive Substances: Regulating the NLRP3 Inflammasome in Autoimmune Diseases

Contact Info

Product

Resources

About